One of the diseases that has caused the most damage has been VIH PAGE. To treat it, a large number of medications are needed. Recent treatment may be able to fight the disease and thus reduce the amount of drugs consumed.
The FDA has approved Cabenuva. It is a sustained-release injectable suspension that essentially contains cabotegravir and rilpivirine. These have been packaged together for intramuscular use. It is the first injectable treatment approved by the Food and Drug Administration for adults with HIV-1, and it is given once a month. Below we will provide more information about this important achievement:
How does it work
Before starting this treatment, the FDA also approved the use of Vocabria (cabotegravir) 30 mg tablets, to be taken with oral rilpivirine (Edurant). This treatment should be followed for a month before starting Cabenuva. This is done to ensure that the drugs can be tolerated by the body before switching to the injected formula.
Vocabria is an inhibitor that, combined with Edurant, inhibits the transfer of the HIV-1 integrase chain in adults with virological suppression on stable antiretroviral treatment.
The stability of this treatment is important because If cabotegravir is tolerated by the body before using cabenuva injections, the medication will work correctly.
There are various tests to find other HIV treatments. However, so far, this is the most effective.
To begin with, the recommended dose is one 30 mg tablet of Vocabria and one 25 mg tablet of Edurant. This treatment should be followed for a month.
Then comes the intramuscular injection with Cabenuva. The starting dose should be 600 mg of cabotegravir and 900 mg of rilpivirine. As recommended by authorities, the first injection should be given on the last day of pill treatment.
After the first dose, the recommended monthly doses of Cabenuva consist of a single intramuscular injection of 400 mg of cabotegravir and one intramuscular injection of 600 mg of ripivirine. The administration site on the buttocks should be separate.
This means that it is not advisable to inject them in the same place, and they must be placed the same day. The injection can be received up to 7 days before or after the scheduled date of administration of the medication.
This medicine should not be given to patients who have a previous sensitive reaction to cabotegravir or rilpivirine. It is also not advisable to supply it if the patient are taking anticonvulsants such as carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; Antimycobacterials such as: rifabutin, rifampin, rifapentine; glucocorticoid such as dexamethasone; and plant-based products, such as St. John’s wort.
It is also important to consider the different side effects. That is why it is advisable to consult a specialist to find out if you are a candidate for this treatment.
It is important to be aware of how the disease works, how to prevent it and what options people with HIV have to improve their quality of life, such as this treatment.
You may also like:
How can we help friends who have contracted HIV?
COVID-19: What we have learned from the fight against HIV / AIDS
Eddie is an Australian news reporter with over 9 years in the industry and has published on Forbes and tech crunch.